The estimated Net Worth of Arie Mayer is at least $141 Тысяча dollars as of 3 April 2023. Arie Mayer owns over 8,809 units of Oramed Pharmaceuticals, Inc stock worth over $63,805 and over the last 5 years he sold ORMP stock worth over $76,800. In addition, he makes $0 as Independent Director at Oramed Pharmaceuticals, Inc.
Arie has made over 2 trades of the Oramed Pharmaceuticals, Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 8,809 units of ORMP stock worth $19,556 on 3 April 2023.
The largest trade he's ever made was buying 8,809 units of Oramed Pharmaceuticals, Inc stock on 3 April 2023 worth over $19,556. On average, Arie trades about 1,687 units every 74 days since 2020. As of 3 April 2023 he still owns at least 26,809 units of Oramed Pharmaceuticals, Inc stock.
You can see the complete history of Arie Mayer stock trades at the bottom of the page.
Dr. Arie Mayer Ph.D. serves as Independent Director of the Company. Dr. Mayer, is currently the Managing Director and Chairman of the Board of Merck Life Science Israel (formerly Sigma-Aldrich Israel Ltd.) and has held that position since January 2010. Dr. Mayer has held various roles with Sigma-Aldrich Israel Ltd. since 1995 and was instrumental in introducing and developing the Cell Culture and Molecular Biology business for Sigma Aldrich Israel Ltd. Dr. Mayer holds a Bachelor of Science degree in chemistry from Hebrew University and a Ph.D. in biochemistry from Israel Institute of Technology.
Arie Mayer is 63, he's been the Independent Director of Oramed Pharmaceuticals, Inc since 2019. There are 3 older and 11 younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.
Arie's mailing address filed with the SEC is 16 MORAN STREET, , KFAR SABA, L3, 4428890.
Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank и Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include: